The Medical Advisor

Introduction Parkinson’s disease is often described as a condition caused by low dopamine. While this is technically correct, it is also incomplete. Emerging research suggests that Parkinson’s is not just a neurotransmitter deficiency—but a complex metabolic and neurodegenerative disorder involving mitochondrial dysfunction, insulin resistance, and chronic inflammation. Understanding this broader picture opens the door to new prevention and treatment strategies that go beyond dopamine replacement. What Happens in Parkinson’s Disease? Parkinson’s disease occurs when dopamine-producing neurons in the substantia nigra progressively die. This leads to: Tremors Muscle rigidity Slowed movement (bradykinesia) Balance and coordination issues Dopamine plays a central role in regulating movement, but its depletion is only the final step in a much larger disease process. Why Dopamine Alone Is Not the Full Story Traditional treatment focuses on replacing dopamine (e.g., levodopa). While effecti...

Introduction: A Paradigm Shift in Neurodegenerative Disease For decades, neurodegenerative diseases like Parkinson’s disease (PD) and Alzheimer’s disease (AD) were viewed primarily through the lens of protein pathology : α-synuclein in PD Amyloid-β and tau in AD Yet, despite billions invested in targeting these proteins, clinical outcomes have been modest at best . A new paradigm is emerging: Neurodegeneration may fundamentally be a disorder of impaired brain energy metabolism. Across PD and AD, researchers consistently observe: Reduced glucose uptake in the brain Mitochondrial dysfunction Insulin resistance (“type 3 diabetes” in AD) Increased oxidative stress This has led to growing interest in metabolic therapies—interventions that aim to restore brain energy supply, improve mitochondrial function, and stabilize neuronal survival. Section 1: The Brain Energy Crisis 1.1 Glucose Hypometabolism One of the earliest detectable abnormalities in Alzheimer’s disease is: Reduced cerebral gluc...

Parkinson’s disease, a progressive neurodegenerative disorder, affects millions worldwide, causing debilitating symptoms like tremors, rigidity, and cognitive decline. As researchers continue to explore innovative treatments, one unexpected candidate has emerged: ivermectin, a drug traditionally used to treat parasitic infections. Recent studies have sparked curiosity about its potential neuroprotective effects, prompting questions about whether this widely available medication could offer hope for managing or even slowing the progression of Parkinson’s disease. In this article, we delve into the science behind ivermectin’s potential role in Parkinson’s treatment, examining the latest research, mechanisms of action, and what this could mean for patients seeking new therapeutic options. Can Ivermectin play a key role in treating Parkinson's Disease? Two peer-reviewed papers—one by Warnecke et al. (2020) and another by Wadsworth et al. (2024)—along with a 2021 PhD thesis by ...

Abstract:   Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra, leading to motor and non-motor symptoms. Recent studies have explored the potential of repurposing existing drugs to complement current PD treatments. Ivermectin, traditionally used as an antiparasitic agent, has emerged as a candidate due to its effects on dopaminergic pathways. This review examines recent research investigating ivermectin's role in modulating dopamine-related behaviors and its potential as an adjunct therapy in PD. Introduction:   Parkinson's disease affects millions worldwide, presenting with symptoms such as tremors, bradykinesia, rigidity, and postural instability. Current treatments primarily focus on dopamine replacement strategies, notably with levodopa (L-DOPA). However, long-term use of L-DOPA can lead to complications, including motor fluctuations and dyskinesias. The search for adjunct therap...

Parkinson's disease is a neurological disorder in which neurons and dopamine-producing cells in your brain begin to die. Symptoms progress over time and include tremors, slow movements, rigid limbs, shuffling gait, stooped posture and an inability to move. Patients may also experience a reduced ability to make facial expressions. Image credit: Grok 2 While patients suffer significant physical disability, the condition may also trigger depression, speech impediments and personality changes. There is also an association with dementia. Parkinson’s affects as many as 7 million to 10 million adults worldwide, and approximately 60,000 Americans are diagnosed with Parkinson's every year. (1) Although incidence of the disease increases with age, an estimated 4% of those with Parkinson's are diagnosed before the age of 50. Men are 1.5 times more likely to have Parkinson's than women, and treatment can be expensive. Medications can an average $2,500 a year, while therapeutic surg...